DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Repurposing the Open Global Health Library for the discovery of novel Mpro destabilizers with scope as broad-spectrum antivirals
The SARS coronavirus 2 (SARS-CoV-2) epidemic remains globally active. The emergence of new variants of interest and variants of concern (VoCs), which are potentially more vaccine-resistant and less sensitive to existing treatments, is evident due to their high prevalence. The prospective spread of such variants and other coronaviruses with epidemic potential demands preparedness that can be met by developing fast-track workflows to find new candidates that target viral proteins with a clear in vitro and in vivo phenotype. Mpro (or 3CLpro) is directly involved in the viral replication cycle and the production and function of viral polyproteins, which makes it an ideal target. The biological relevance of Mpro is highly conserved among betacoronaviruses like HCoV-OC43 and SARS-CoV-2, which makes the identification of new chemical scaffolds targeting them a good starting point for designing broad-spectrum antivirals. We report an optimized methodology based on orthogonal cell-free assays to identify small molecules that inhibit the binding pockets of both SARS-CoV-2-Mpro and HCoV-OC43-Mpro; this blockade correlates with antiviral activities in HCoV-OC43 cellular models. By using such a fast-tracking approach against the Open Global Health Library (Merck KGaA), we have found evidence of the antiviral activity of compound OGHL98. In silico studies dissecting intermolecular interactions between OGHL98 and both proteases and comprising docking and molecular dynamics simulations (MDSs) concluded that the binding mode was primarily governed by conserved H-bonds with their C-terminal amino acids and that the rational design of OGHL98 has potential against VoCs proteases resistant to current therapeutics., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. DG-P’s laboratory and research have been funded by the European Commission—Next Generation EU (regulation EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global), the Instituto de Salud Carlos III Subdirección General de Redes y Centros de Investigación Cooperativa-Red de Investigación Cooperativa en Enfermedades Tropicales (RICET: RD16/0027/0014), and the MCIN/AEI/10.13039/501100011033, and by the grants PID2019-109623RB-I00, MCIN/AEI/10.13039/501100011033, and FEDER Una manera de hacer Europa (2016-
79957-R), and PID2022-142971OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE, and by the Junta de Andalucía (BIO-199). DR’s research has been funded by the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT), grant number
1220656, and the Agencia Nacional de Investigación y Desarrollo (ANID), grant number COVID0199., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-109623RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-142971OB-I00
DOI: http://hdl.handle.net/10261/368570, https://api.elsevier.com/content/abstract/scopus_id/85199364617
HANDLE: http://hdl.handle.net/10261/368570, https://api.elsevier.com/content/abstract/scopus_id/85199364617